Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Maastricht University Medical Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04954599CT.gov Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer Of Unknown Primary Site
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cp-506 (this asset) | Maastricht University Medical Center | P1/2 | CC · 47 |
| Amifostine | M.D. Anderson Cancer Center | P4 | BBB |
| Nepenthe | M.D. Anderson Cancer Center | P4 | BBB |
| Dexasone | Alliance for Clinical Trials in Oncology | P3 | BBB |
| Etoposide | University of California, Davis | P2/3 | BBB |
| Docetaxel | University of Wisconsin, Madison | P2 | BBB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BBB |
| Melphalan | City of Hope Medical Center | P2/3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
+42 more in the Cancer Of Unknown Primary Site cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cp-506 in Cancer Of Unknown Primary Site. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cp-506-cancer-of-unknown-primary-site
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →